Hyperlipoproteinemia type 5

Jump to navigation Jump to search

WikiDoc Resources for Hyperlipoproteinemia type 5

Articles

Most recent articles on Hyperlipoproteinemia type 5

Most cited articles on Hyperlipoproteinemia type 5

Review articles on Hyperlipoproteinemia type 5

Articles on Hyperlipoproteinemia type 5 in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Hyperlipoproteinemia type 5

Images of Hyperlipoproteinemia type 5

Photos of Hyperlipoproteinemia type 5

Podcasts & MP3s on Hyperlipoproteinemia type 5

Videos on Hyperlipoproteinemia type 5

Evidence Based Medicine

Cochrane Collaboration on Hyperlipoproteinemia type 5

Bandolier on Hyperlipoproteinemia type 5

TRIP on Hyperlipoproteinemia type 5

Clinical Trials

Ongoing Trials on Hyperlipoproteinemia type 5 at Clinical Trials.gov

Trial results on Hyperlipoproteinemia type 5

Clinical Trials on Hyperlipoproteinemia type 5 at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Hyperlipoproteinemia type 5

NICE Guidance on Hyperlipoproteinemia type 5

NHS PRODIGY Guidance

FDA on Hyperlipoproteinemia type 5

CDC on Hyperlipoproteinemia type 5

Books

Books on Hyperlipoproteinemia type 5

News

Hyperlipoproteinemia type 5 in the news

Be alerted to news on Hyperlipoproteinemia type 5

News trends on Hyperlipoproteinemia type 5

Commentary

Blogs on Hyperlipoproteinemia type 5

Definitions

Definitions of Hyperlipoproteinemia type 5

Patient Resources / Community

Patient resources on Hyperlipoproteinemia type 5

Discussion groups on Hyperlipoproteinemia type 5

Patient Handouts on Hyperlipoproteinemia type 5

Directions to Hospitals Treating Hyperlipoproteinemia type 5

Risk calculators and risk factors for Hyperlipoproteinemia type 5

Healthcare Provider Resources

Symptoms of Hyperlipoproteinemia type 5

Causes & Risk Factors for Hyperlipoproteinemia type 5

Diagnostic studies for Hyperlipoproteinemia type 5

Treatment of Hyperlipoproteinemia type 5

Continuing Medical Education (CME)

CME Programs on Hyperlipoproteinemia type 5

International

Hyperlipoproteinemia type 5 en Espanol

Hyperlipoproteinemia type 5 en Francais

Business

Hyperlipoproteinemia type 5 in the Marketplace

Patents on Hyperlipoproteinemia type 5

Experimental / Informatics

List of terms related to Hyperlipoproteinemia type 5

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] ;Associate Editor(s)-in-Chief: Shivani Chaparala M.B.B.S [2]

Synonyms and keywords: : Hyperchylomicronemia,Late-Onset, Hyperchylomicronemia With Hyperprebetalipoproteinemia, Familial, Mixed Hyperlipidemia, Type V Hyperlipemia, Hyperlipidemia Type V, Type 5 Hyperlipoproteinemia, Type 5 Hyperlipemia, Type 5 HPL, Type V HPL, Combined Fat And Carbohydrate Induced Hyperlipidemia, Mixed Hypertriglyceridemia.

Overview

Hyperlipoproteinemia type 5 is a severe type of autosomal dominant inherited hyperlipidemia, characterised by inability to break down triglycerides and cholesterol which results in increase levels of chylomicrons and VLDL. It is a more complicated form of type I and more closely related with acquired environmental factors but no association with reduced Lipoprotein lipase or apolipoprotein C-II activity as in type I.

Pathophysiology

The absence of manifestations until middle age, suggest that the cause of type V hyperlipoproteinemia(HPL) is multifactorial including a combination of environmental, hormonal and genetic factors. Type V may be found in families with other forms of hyperlipoproteinemias such as type III and type IV. VLDL appears to be the most affected lipoproteien fraction in type V and there is 3fold increase in synthesis rate as well as decreased fractional catabolism of VLDL.

Genetics

Precise genetic patterns have not been determined for type V HLP and it has been suggested that type V may be due to number of genetic defects. Among them, the apo E and its isoforms may have an important clinical significance in type V HPL and may affect the catabolism of triglyceride rich lipoproteins. The presence of apo E4 allele may be the genetic factor that predisposes to the development of type V due to delayed lipoprotein clearance.

Associated Conditions

Type V HPL is associated with insulin-dependent diabetes mellitus, alcohol abuse, glycogen storage disease type I, Hyperuricemia, Pancreatitis and xanthomatosis.

Causes

Causes of type V hyperlipoproteinemia is more complicated and more closely related to acquired environmental factors. It rarely shows familial occurrence, but its inheritance is variable. Therefore, type V HLP is usually considered to be triggered by acquired environmental factors in individuals with some congenital susceptibility to altered triglyceride metabolism (genetic factors). While the inovolved environmental factors vary, involvement of heavy dirinking, type 2 Diabetes, hormonal therapy and medications are frequently observed.

Epidemiology and Demographics

Average triglyceride levels in type V hyperlipoproteinemia are lower for women than for men before age 50.

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Criteria

If available, the diagnostic criteria are provided here.

History

A directed history should be obtained to ascertain

Symptoms

"Type symptom here" is pathognomonic of the "type disease name here".

"Type non specific symptoms" may be present.

Past Medical History

Family History

Social History

Occupational

Alcohol

The frequency and amount of alcohol consumption should be characterized.

Drug Use

Smoking

Allergies

Physical Examination

Appearance of the Patient

Vital Signs

Skin

Head

Eyes

Ear

Nose

Mouth

Throat

Heart

Lungs

Abdomen

Extremities

Neurologic

Genitals

Other

Laboratory Findings

Electrolyte and Biomarker Studies

Electrocardiogram

Chest X Ray

CT

MRI

Echocardiography or Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Pharmacotherapy

Acute Pharmacotherapies

Chronic Pharmacotherapies

Surgery and Device Based Therapy

Indications for Surgery

Pre-Operative Assessment

Post-Operative Management

Transplantation

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

References